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Global efforts in the control and prevention of malaria from 2000 
to 2015 have dramatically reduced both the incidence (37%) and 
mortality (60%) rate due to malaria infections; however, the threat 
of parasite resistance is still threatening and could undermine such 
achievements. Three of the five Plasmodium species which are 
known to infect humans (P. falciparum, P. vivax and P. malariae) 
have all demonstrated resistance to common use antimalarials.1 
With resistance to Artemisnin monotherapy and also combination 
therapy (ACT) reported as a delayed clearance of infection with 
standard dosing regimens, there is a need for new antimalarial 
compounds.2 Those with alternative modes of action are of most 
value as cross-resistance generated to all compounds within the 
same chemical class or mode of action is a common phenomenon.1 
Although work towards this goal is progressing, such as with 
DDD107498, there is still need to maintain a pipeline of potential 
novel therapeutics should resistance emerge.3 A number of 
screening campaigns have identified new drug candidates which 
appear to be clustering to a small number of targets, for example 
PfATP4,4 PI4K5 and PfDHODH6. The identification of 
compounds with alternative targets or modes of action is an 
obvious direction to take in order to minimize the threat of cross-
resistance.  
Minor groove binders (MGBs) are class of compound that 
bind to the minor groove of DNA and have found use as both 
human and animal antimicrobial therapies.7-10 Of particular 
note is a class of MGB that is based on arylamidines such as 
berenil, pentamidine and DB75 (Figure 1), that have significant 
activity against many parasitic microorganisms.8, 11 
Pentamidine has been used clinically for over 60 years to treat 
many infectious diseases in humans, particularly human 
African trypanosomiasis; however, it has issues with adverse 
side effects and poor oral availability.12  The arylamidines were 
used as the basis of a synthesis campaign by Boykin and 
coworkers which lead to the discovery of DB75, furamidine 
(Figure 1), a highly active antitrypanosomal drug in animal 
studies, and an orally available prodrug of it, DB289,  
pafuramidine (Figure 1).13, 14 Possible renal toxicity in the later 
clinical trials lead to the development DB289 being paused; 
however, this near clinical success serves to highlight the 
potential of MGBs as antiparasitic therapies.11 
 
Figure 1. Examples of arylamidine minor groove binders.  
Strathclyde minor groove binders (S-MGBs) make up a family 
of DNA-binding compounds loosely built upon the structure of 
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distamycin as a template but including a very wide range of 
structural components so that an extensive coverage of structural 
and property space can be obtained within the same DNA- binding 
template (Figure 2).15,16 The principal variables are the head groups 
and their linkage to the rest of the molecule (amidine, amide, or 
alkene), the heterocyclic building blocks, the alkyl substituents on 
the heterocyclic building blocks, and the basicity of the C-terminal 
tail group. By manipulating these variables potent antibacterial 
compounds have been discovered, one of which has completed 
phase 1 clinical trials,17 and other compounds have been shown to 
be active against Trypanosoma both in cell-based studies and in 
mouse models of disease and leishmaniasis (unpublished 
results).18, 19 A potential benefit of targeting DNA is that it is to be 
expected that several binding sites will be occupied by S-MGBs 
leading to multiple mechanisms of action, which in turn could 
mitigate risks of rapid development of resistance. A counter 
balancing risk is that the ubiquity of DNA makes species 
selectivity critical. Studies of S-MGBs have shown that selectivity 
can be obtained between different infectious agents and 
mammalian cells with sufficient therapeutic ratios to indicate that 
candidate drugs can be obtained.15, 16, 20 This paper describes the 
evaluation of a subset of S-MGBs covering the three head group 
linking types together with other variations in the context of 
antimalarial drug discovery comparing the activity in a 
chloroquine sensitive (3D7) and resistant (Dd2) strain of 
Plasmodium falciparum. 
 
Figure 2. Examples of structures within S-MGBs. Using the shorthand structure code in the table, the 
head group fragments are 3-MeOC6H4(am)-PyMe-; 3-MeOC6H4-PyMe-; 3-MeOC6H4=C6H-. The 
compound examples are 3-Isoquin-PyMe-PyMe-PyMe-MorphE and 3-Isoquin-PyMe-PyMe-DMAP. 
The syntheses of the compounds evaluated have been described 
previously and all samples assayed were greater than 98% pure by 
HPLC and 1H NMR.15, 16 As shown in Table 1, the structures of the 
compounds included the three head group types (figure 1) with a 
range of polar and non-polar substituents, N-alkyl pyrroles, a 
standard feature of minor groove binders, C-alkyl thiazoles, a 
specific feature of S-MGBs, and a basic tertiary amine 
(dimethylamino) or weakly basic amine (morpholino) tail group. 
The C-alkyl thiazole is significant in that it promotes binding at 
GC sites in DNA whereas N-alkyl pyrroles bind preferentially at 
AT sites.21 Different combinations of these components allow for 
a wide range of DNA-binding and physicochemical properties to 
be covered in a small number of compounds. For example, the 
clogD7.4 values for the set range between -3.28 and 6.97 (Table 
1).19 
Compound inhibitory activity was determined in IC50 dose 
response format against Pf3D7 (chloroquine sensitive) and PfDd2 
(chloroquine resistant) stains using a previously described high 
content imaging assay.22 In addition, compounds were 
simultaneously tested for general cytotoxicity against HEK293 
cells using an AlamarBlue based assay which measures cell 
metabolic activity. All compounds were tested in duplicate point 
in 22 doses in two separate experiments. 
The data shown in Table 1 illustrate both significantly active 
and inactive compounds (Structures shown in ESI). No significant 
activity was observed in compounds without an aromatic head 
group (2, 8). Encouraging activity and selectivity were found 
almost entirely within the alkene-linked subset of compounds; the 
amidine-linked compounds were all at best weakly active and only 
one amide-linked compound had significant activity (12). 
Interestingly, this compound contains a C-alkylthiazole with a 
branched alkyl chain (i-propyl), a structural feature that seems to 
promote antimalarial activity. Overall, five of the most active 
compounds, all alkene linked, contained a C-alkylthiazole (18-21, 
22, 23, 25). Even in the weakly active amidine series, the C-
alkylthiazole noticeably increased the activity (compare 3 and 5). 
Importantly, approximately equal activity was observed between 
the resistant and sensitive strain, there being no statistically 
significant difference between the two data sets (two-tailed sign 
test, p = 1.000). 
The antiparasitic and antibacterial activity of S-MGBs can be 
broadly considered in two principal dimensions, namely binding 
to DNA and access to cells. The latter has been found to be 
particularly important in the differences of behaviour of S-MGBs 
between Gram-positive and Gram-negative bacteria; antibacterial 
activity is strongly shown against the former but not the latter and 
there is good evidence that for Gram-negative bacteria, efflux 
pumps prevent the S-MGBs from reaching the target DNA 
(unpublished results). Interaction of S-MGBs with efflux pumps 
appears to be related to their physicochemical characteristics. 
These properties could also be relevant in antimalarial activity. 
Taking logD7.4 as a measure of lipophilicity, these data suggest that 
a minimum value of about 2.9 is necessary for modest activity 
(IC50 < 2 PM) against the two strains of P. falciparum tested.  
Using these data as a guide it is possible to suggest that the most 
polar compounds such as the amidines (1, 2) are unable to reach 
target DNA in plasmodia cells; this effect is evidently mitigated 
by the presence of the C-alkyl thiazole (5, 7) which leads to 
significantly higher logD7.4 values and activity less that 2 PM. 
Significant sub-micromolar activity, however, is restricted to the 
alkene series (18-21, 22, 23, 25, 26) and one amide (12); in the 
alkene series, the logD7.4 values span a wide range (4.14 ± 7.67) 
indicating that this parameter alone cannot account for the activity 
observed (Figure 3). Equally, it appears that toxicity as measured 
in HEK cells is not directly related to lipophilicity, which is 
significant for potential optimization of the leads. 
Figure 3. The relationship between activity and lipophilicity. The two most active compounds are 
shown in green. Those with measurable toxicity against HEK cells are shown in red. 
 As noted above, the presence of the C-alkyl thiazole appears to 
be significant. It is also plausible that Plasmodia could have a GC 
base pair at the DNA binding site of the S-MGB, unlike the 
antibacterial compounds, which are predominantly AT readers; 
this is notable bearing in mind the low GC content in the P. 
falciparum genome.23 It is also notable that none of the compounds 
in this set showed high antibacterial activity, further emphasizing 
that selectivity of action is possible with S-MGBs. 
  
Compound 
% Inhibition or  
IC50  
P. falciparum 
3D7           (nM) 
% Inhibition or  
IC50  
P. falciparum 
Dd2           (nM) 
% Inhibition or 
IC50 HEK cells     
(na = no effect @ 
20 PM) 
Selectivity 
HEK/3D7 
logD7.4 
Amidines      
1 90% @ 20 PM 63% @ 20 PM na  -0.35 
2 6422 6457 na  -3.28 
3 2731 2970 na  3.2 
4 9980 100% @ 20 PM na  0.48 
5 na 35% @ 20 PM na  1.23 
6 3384 2773 40% @ 10 PM  0.35 
7 1997 1507 76% @ 20 PM  3.12 
Amides      
8 98% @ 20 PM 25% @ 20 PM na   -0.13 
9 1800 3072 na   2.99 
10 3035 3617 na   2.91 
11 75% @ 20 PM 65% @ 20 PM na  1.16 
12 469 636 na >42 3.82 
13 7860 5990 na   1.86 
14 4312 3267 na   1.62 
15 4701 4348 na   0.02 
16 1409 1999 na   2.79 
17 5491 4479 na   0.39 
 Alkenes          
18 437 288 7.65 PM  15.8 5.13 
19 544 1132 86% @ 20 PM > 36 4.82 
20 868 1148 5.8* 6.7 4.82 
21 350 339 60% @ 20 PM >14 4.14 
22 322 289 54% @ 20 PM > 60 5.74 
23 390 588 na > 50 7.57 
24 3570 3691 na   4.68 
25 103 241 na > 194 6.97 
26 780 923 63% @ 20 PM > 26 2.58 
27 39 38 na > 514 3.37 
28 3297 3341 na   3.94 
29 3322 2747 na   3.94 
30 6037 5144 na   3.95 
31 1926 2302 na   3.15 
32 1947 2986 na   4.04 
33 1766 1899 na   4.82 
Controls      
Puromycin 60 62 0.350 6 - 
Pyrimethamine 8.45 >120uM 8.07 955 - 
Chloroquine 11.35 177 >120 >10000 - 
Artemisinin 7.75 9 >120 >10000 - 
Table 1. Biological compounds of S-MGBs evaluated in this study. LogD7.4 predicted using the software MarvinSketch (Version 15.6.29.0, ChemAxon, http://www.chemaxon.com).
The therapeutic ratio between infected and non-infected cells is 
also an important criterion in assessing the potential of compounds 
as leads for drug discovery. In this study, the viability of HEK cells 
was used as the measure of potential cytotoxicity to a human host. 
Unsurprisingly compounds that contained a known toxophore 
(aromatic nitro groups, 21, 22) showed toxicity when HEK cells 
were treated with 20 PM S-MGB. Even these compounds, 
however, had a reasonable therapeutic ratio (>14, >60) and other 
compounds (12, 14, 18, 19, 21) were comparable in this respect. 
The equivalent activity witnessed for both the Plasmodium 
falciparum strains demonstrates no common resistance 
mechanism shared by these compounds.  
One compound (27), with the benzoxazole containing head 
group stands outside this analysis with a logD7.4 appropriate for 
further development (3.37) and high antiparasitic activity (~ 40 
nM) which, in the absence of a C-alkylthiazole, imply a significant 
and unexpected role for the head group. This result is also 
surprising because S-MGBs (26, 30 - 32) with other strongly 
hydrogen bonding aromatic head groups and otherwise identical 
structures in the rest of the S-MGB were greatly inferior even if 
the logD7.4 value was similar to that of 27 as is the case with the 
oxadiazole, 31. 
There are many structural variables to manipulate in the S-
MGB structure. This study shows that active and selective 
compounds can be found with both moderate and high logD7.4 
values (25 and 27, Figure 4). It would normally be expected that 
the compound with the lower logD7.4 has the greater potential for 
development into a drug and the benzoxazole head group in 27 has 
scope for incorporation into compounds containing the C-alkyl 
thiazoles, which were found to promote activity in many 
compounds. Perhaps the most important conclusion from this 
study is that S-MGBs are active against P. falciparum including a 
chloroquine-resistant strain and have a good potential therapeutic 
window (> 200 - > 500) for further development into lead 
optimization.  
 
Figure 4. The two most active compounds (25 and 27) found in this study. 
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